228 related articles for article (PubMed ID: 18975354)
21. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.
Schett G; Stolina M; Dwyer D; Zack D; Uderhardt S; Krönke G; Kostenuik P; Feige U
Arthritis Rheum; 2009 Sep; 60(9):2644-54. PubMed ID: 19714640
[TBL] [Abstract][Full Text] [Related]
22. Differential cytokine expressions affect the severity of peri-implant disease.
Duarte PM; de Mendonça AC; Máximo MB; Santos VR; Bastos MF; Nociti Júnior FH
Clin Oral Implants Res; 2009 May; 20(5):514-20. PubMed ID: 19302394
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.
Naumann L; Huscher D; Detert J; Spengler M; Burmester GR; Buttgereit F
Ann Rheum Dis; 2009 Dec; 68(12):1934-6. PubMed ID: 19910303
[No Abstract] [Full Text] [Related]
24. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
Wang J; Wang K; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
[TBL] [Abstract][Full Text] [Related]
25. Effect of estrogen on bone resorption and inflammation in the temporomandibular joint cellular elements.
Galal N; El Beialy W; Deyama Y; Yoshimura Y; Yoshikawa T; Suzuki K; Totsuka Y
Int J Mol Med; 2008 Jun; 21(6):785-90. PubMed ID: 18506373
[TBL] [Abstract][Full Text] [Related]
26. Lessons from magnetic resonance imaging studies in rheumatoid arthritis.
Quinn M
J Rheumatol; 2008 Mar; 35(3):372-4. PubMed ID: 18322971
[No Abstract] [Full Text] [Related]
27. [Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis].
Głuszko P
Endokrynol Pol; 2009; 60(2):115-21. PubMed ID: 19396755
[TBL] [Abstract][Full Text] [Related]
28. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
Walker JG; Ahern MJ; Coleman M; Weedon H; Papangelis V; Beroukas D; Roberts-Thomson PJ; Smith MD
Ann Rheum Dis; 2006 Dec; 65(12):1558-64. PubMed ID: 16760256
[TBL] [Abstract][Full Text] [Related]
29. Trials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et al.
Porter D
Ann Rheum Dis; 2008 Sep; 67(9):1356. PubMed ID: 18697785
[No Abstract] [Full Text] [Related]
30. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis.
Kirwan J; Power L
Curr Opin Rheumatol; 2007 May; 19(3):233-7. PubMed ID: 17414948
[TBL] [Abstract][Full Text] [Related]
31. Novel approaches to discovery of biomarkers in rheumatoid arthritis: comment on the article by Oswald et al.
Hudson M; Baron M; Colmegna I; Bernatsky S; Klein Oros K; Pastinen T; Greenwood C
Arthritis Rheumatol; 2015 May; 67(8):2276-7. PubMed ID: 25988805
[No Abstract] [Full Text] [Related]
32. Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al.
Sandoo A; Toms T; Zanten JV; Carroll D; Kitas G
Arthritis Rheum; 2009 Jun; 61(6):854-5; author reply 855-6. PubMed ID: 19479694
[No Abstract] [Full Text] [Related]
33. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
Weisman MH
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
[No Abstract] [Full Text] [Related]
34. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
35. Interaction of human recombinant tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin could contribute to enhancement of the erosive processes induced by human synovial cells.
Narducci P; Bareggi R; Nicolin V
J Rheumatol; 2009 Aug; 36(8):1837-9. PubMed ID: 19671825
[No Abstract] [Full Text] [Related]
36. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
Kavanaugh A
Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
[No Abstract] [Full Text] [Related]
37. Anti-arthritic and disease modifying activity of Terminalia chebula Retz. in experimental models.
Nair V; Singh S; Gupta YK
J Pharm Pharmacol; 2010 Dec; 62(12):1801-6. PubMed ID: 21054408
[TBL] [Abstract][Full Text] [Related]
38. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
39. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
Radovits BJ; Kievit W; Fransen J; van de Laar MA; Jansen TL; van Riel PL; Laan RF
Ann Rheum Dis; 2009 Sep; 68(9):1470-3. PubMed ID: 19015210
[TBL] [Abstract][Full Text] [Related]
40. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
Smolen JS; Aletaha D
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
